Eli Lilly’s $6.3B Centessa Deal Signals Sleep Drug Race
Eli Lilly is reportedly acquiring sleep-drug maker Centessa for $6.3B, underscoring how aggressively big pharma is moving to secure differentiated CNS and sleep...
#biotech acquisition
All topics tagged with #biotech acquisition
Novartis’ $2B Excellergy deal signals allergy drug boom
Novartis plans to acquire allergy biotech Excellergy for $2B, underscoring accelerating big-pharma demand for differentiated immunology and allergy pipelines. T...